ENTA is the best / safest / cheapest Hep-C company out there. It could earn about $8 EPS in 2014 from 195 million in milestone payments and $10+ next year from royalties of Abvie's Hep-C drug (and more milestone payments) which will be competing with Gilead. Of course, the drug is not approved yet. However, it is almost certainly going to get approved in Dec as it got priority review.It hit an all time high of $44.48 today. But this is still cheap compared to what its EPS can be this year (150 million milestone payments) and next year and beyond
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ra